E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts.
Mann
M J
MJ
Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02115, USA.
D000818:Animals; D001161:Arteriosclerosis / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D001807:Blood Vessel Prosthesis; D002315:Cardiopulmonary Bypass; D002352:Carrier Proteins; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins; D015195:Drug Design; D050684:E2F Transcription Factors; D005786:Gene Expression Regulation / Q000187:drug effects*; D015316:Genetic Therapy; D006083:Graft Occlusion, Vascular / Q000473:pathology / Q000517:prevention & control*; D006131:Growth Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia; D006984:Hypertrophy; D005810:Multigene Family; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology; D010957:Plasmids / Q000235:genetics; D011817:Rabbits; D056465:Retinoblastoma-Binding Protein 1; D013329:Structure-Activity Relationship; D050680:Transcription Factor DP1; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000502:physiology; D014162:Transfection; D017539:Tunica Intima / Q000293:injuries / Q000378:metabolism / Q000473:pathology
D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D006131:Growth Inhibitors; D056465:Retinoblastoma-Binding Protein 1; D050680:Transcription Factor DP1; D014157:Transcription Factors